Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome

Although dopamine agonists are becoming first‐line therapy for restless legs syndrome (RLS), few reports describe treatment periods exceeding 12 weeks. Here, 150 RLS patients who had responded to pramipexole during a 6‐month run‐in period (mean dose, 0.50 mg) were randomly assigned to receive placeb...

Ausführliche Beschreibung